Lova Sun, MD, MSCE, discussions safety implications observed from part C of the phase 2 innovaTV 207 trial.
Lova L. Sun, MD, MSCE
Advertisement
Articles by Lova L. Sun, MD, MSCE
Lova L. Sun, MD, MSCE discusses tisotumab vedotin (in patients with recurrent or metastatic (r/m) head and neck squamous cell carcinoma.
Lova L. Sun, MD, MSCE, discusses the association between duration of immunotherapy and overall survival in patients with advanced non–small-cell lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
5